--Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2023 financial results and provided an update on its ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, ...

Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team ...

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results Nov. 08, 2023 6:30 AM ET Beam Therapeutics Inc. (BEAM) Q3: 2023-11-08 Earnings Summary ...

Beam Therapeutics: Expected To Boost Pipeline Development Into 2023. Dec. 09, 2022 5:05 PM ET Beam Therapeutics Inc. (BEAM) Stock CRSP, EDIT, VERV, BEAM 2 Comments 5 Likes. Stella Mwende.

Beam Therapeutics. Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion. Executing First Wave of Long-term Strategy for Sickle Cell ...

Cathie Wood has made big bets on base-editing stocks, including recent purchases of Beam Therapeutics. However, Beam announced a reprioritization of its pipeline last week, raising concerns for ...

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on BEAM stock, giving a Hold rating on August 7. Mani Foroohar&#8217 ...

John Evans, CEO, Beam Therapeutics. Beam Therapeutics. ... increasing to $45,577,000 from $19,354,000 as the company gears up its pipeline development. ...

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported ...

U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed ...